PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34882080-5 2021 Following the TMZ treatment, the leukocyte count in peripheral blood was decreased (5.3 %; r<0.01) and the serum concentration of high-sensitivity C-reactive protein was decreased (30.7 %; r<0.01) vs. increases of these indexes in the control group (17.9 %; r<0.05 and 17.8 %; r<0.05, respectively). Trimetazidine 14-17 C-reactive protein Homo sapiens 147-165 11836849-0 2001 The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction. Trimetazidine 14-27 C-reactive protein Homo sapiens 31-49 27446307-7 2016 After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Trimetazidine 36-49 C-reactive protein Homo sapiens 80-83 25864742-0 2015 Effect of trimetazidine on serum interleukin-6 and C-reactive protein concentrations in patients with stable coronary artery disease. Trimetazidine 10-23 C-reactive protein Homo sapiens 51-69 25864742-14 2015 Moreover, it resulted in the reduction of CRP concentration The increase of IL-6 concentration after three-month trimetazidine treatment and the lack of changes of its concentration after TET is associated with yet another mechanism of trimetazidine. Trimetazidine 236-249 C-reactive protein Homo sapiens 42-45 29285227-10 2017 Results: Compared with the control group, the trimetazidine group had a lower frequency of patients with post-PCI serum CK-MB and cTnI levels higher than normal values; the trimetazidine group had also significantly lower serum hs-CRP and TNF-alpha levels, and higher IL-10 levels post-PCI. Trimetazidine 46-59 C-reactive protein Homo sapiens 231-234 29285227-10 2017 Results: Compared with the control group, the trimetazidine group had a lower frequency of patients with post-PCI serum CK-MB and cTnI levels higher than normal values; the trimetazidine group had also significantly lower serum hs-CRP and TNF-alpha levels, and higher IL-10 levels post-PCI. Trimetazidine 173-186 C-reactive protein Homo sapiens 231-234 24797235-8 2014 CONCLUSIONS: TMZ treatment in CHF patients may improve clinical symptoms and cardiac function, reduce hospitalization for cardiac causes, and decrease serum levels of BNP and CRP. Trimetazidine 13-16 C-reactive protein Homo sapiens 175-178 22484413-11 2013 C reactive protein concentrations remained stable throughout the study in trimetazidine group at baseline and at the 6 month on follow up. Trimetazidine 74-87 C-reactive protein Homo sapiens 0-18 16498228-7 2006 Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre- and post-angioplasty periods, but the TNF-alpha levels were significantly decreased only in the post-angioplasty period. Trimetazidine 22-25 C-reactive protein Homo sapiens 33-36 11836849-1 2001 The aim of this randomised, double-blind, placebo controlled, parallel group study was to assess the effect of trimetazidine (TMZ), a potent antiischaemic drug, on plasma C-reactive protein (C-RP), cytokine and adhesion molecule levels. Trimetazidine 111-124 C-reactive protein Homo sapiens 171-189 11836849-1 2001 The aim of this randomised, double-blind, placebo controlled, parallel group study was to assess the effect of trimetazidine (TMZ), a potent antiischaemic drug, on plasma C-reactive protein (C-RP), cytokine and adhesion molecule levels. Trimetazidine 126-129 C-reactive protein Homo sapiens 171-189 11836849-6 2001 Plasma C-RP level was significantly lower in TMZ group (39.5 mg/ml +/- 9.7 mg/ml) as compared to placebo (75.7 +/- 29.4 mg/ml, p < or = 0.001) and peaked 28 hours later in TMZ group. Trimetazidine 45-48 C-reactive protein Homo sapiens 7-11 11836849-6 2001 Plasma C-RP level was significantly lower in TMZ group (39.5 mg/ml +/- 9.7 mg/ml) as compared to placebo (75.7 +/- 29.4 mg/ml, p < or = 0.001) and peaked 28 hours later in TMZ group. Trimetazidine 175-178 C-reactive protein Homo sapiens 7-11 11836849-11 2001 The present study demonstrates a significant reduction of plasma C-reactive protein level in the course of acute myocardial infarction treated with streptokinase and intravenous trimetazidine infusion compared with the group of patients without trimetazidine treatment. Trimetazidine 178-191 C-reactive protein Homo sapiens 65-83 11836849-11 2001 The present study demonstrates a significant reduction of plasma C-reactive protein level in the course of acute myocardial infarction treated with streptokinase and intravenous trimetazidine infusion compared with the group of patients without trimetazidine treatment. Trimetazidine 245-258 C-reactive protein Homo sapiens 65-83